Category: ALK fusion + Lung Cancer

Do you know a ROS1-fusion positive cancer patient?

In May, 2016, the Bonnie J. Addario Lung Cancer Foundation launched the Global ROS1 Initiative, in partnership with cancer patients whose tumors are driven by ROS1 gene fusions. These ROS1 gene fusions are abnormal changes in cells that drive the growth and spread of several different cancer types such as non-small cell lung, gastric, ovarian,… Read More

Posted by Dr. Guneet Walia on February 23rd, 2017

FDA Approves Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer

Genentech’s PDL1 drug approved in the second line setting for people “with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.” http://www.businesswire.com/news/home/20161018006709/en/FDA-Approves-Genentech’s-Cancer-Immunotherapy-TECENTRIQ®-Atezolizumab

Posted by ALCF Staff on October 18th, 2016

Lung Cancer Updates from ASCO 2016

Download PDF of this post What is ASCO? ASCO is the American Society of Clinical Oncology that has an annual meeting each year where key research and clinical medicine highlights are presented by cancer researchers & clinicians to the global community. This was the 52nd Annual Meeting of the American Society of Clinical Oncology, held… Read More

Posted by Dr. Guneet Walia on July 20th, 2016

New Clinical Trial Available for ALK+ NSCLC patients- XALT2

If you have non-small cell lung cancer (NSCLC), you may be interested in learning more about a clinical research study opportunity. Non-small cell lung cancer (NSCLC) is one of two types of lung cancer (the other is small cell lung cancer). Most lung cancers are NSCLC. Of the people who have NSCLC, only 3 percent… Read More

Posted by Danielle Hicks on April 1st, 2016

New Clinical Trial For Patients No Longer Benefitting from Standard Therapy, or For Whom No Standard Therapy is Available

This Monday, the American Society of Clinical Oncology (ASCO) launched its first ever clinical trial that has been designed with a unique format and allows patients with advanced solid tumor (including lung cancer), multiple myeloma, or B cell non-Hodgkin lymphoma who are no longer benefitting from standard anti-cancer treatments, or for whom no acceptable standard… Read More

Posted by Dr. Guneet Walia on March 23rd, 2016

Cancer Patients Value Quality of Life Over Symptom Management

In October at their headquarters in New York City, CancerCare, a national organization that provides free support and financial services to anyone touched by cancer, held a roundtable discussion on “Improving the Quality of Life for Lung Cancer Patients”. It featured key opinion leaders and lung cancer advocates who discussed the importance of an all-inclusive… Read More

Posted by Dr. Guneet Walia on March 10th, 2016

Lung Cancer in Women: Lets do something about it!

Bonnie J. Addario Lung Cancer Foundation partners with the American Lung Association to fund $250,000 on innovative and transformational research to defeat lung cancer in women An unfortunate and often unknown fact is that lung cancer is the leading cancer killer in women, estimated to be the cause of 1 in 4 female cancer deaths… Read More

Posted by Dr. Guneet Walia on February 25th, 2016

Today is World Cancer Day. Here’s how YOU can #BeTheSolution!

Bonnie J. Addario Lung Cancer Foundation Launches $180,000 Crowdsourcing Challenge to Increase Clinical Trial Patient Enrollment. Each year, in honor of World Cancer Day, the Bonnie J. Addario Lung Cancer Foundation (ALCF) launches a unique, international crowdsourcing challenge that leverages the power of the crowd, encouraging innovators from both within and more importantly, outside healthcare… Read More

Posted by Dr. Guneet Walia on February 4th, 2016

Breakthrough Medicines Usher in Hopeful Era for Lung Cancer Patients

The Bonnie J. Addario Lung Cancer Foundation (ALCF) applauds the medical research community and the U.S. Food and Drug Administration (FDA) for putting a heightened focus on lung cancer diagnostics and treatments. ALCF works everyday to educate patients and their families on the latest advancements, encourage participation in clinical trials and fund life-saving research on… Read More

Posted by Dr. Guneet Walia on December 18th, 2015

FDA Approves Alectinib for second-line treatment of ALK+ patients

The US Food and Drug Administration (FDA) today granted accelerated approval to Alectinib (Alecensa) for the treatment of patients with ALK (Anaplastic Lymphoma Kinase)-rearranged metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (Xalkori). ALK-rearrangement positive NSCLC accounts for 5% of all non-small cell lung cancer diagnoses, and typically… Read More

Posted by Dr. Guneet Walia on December 11th, 2015